Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.
about
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1Microscale insights into pneumococcal antibiotic mutant selection windowsDoes High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?Mutant prevention concentration, pharmacokinetic-pharmacodynamic integration, and modeling of enrofloxacin data established in diseased buffalo calves.Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.Drug interactions and the evolution of antibiotic resistance.Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.Mutant selection window and characterization of allelic diversity for ciprofloxacin-resistant mutants of Rhodococcus equi.Selection of target mutation in rat gastrointestinal tract E. coli by minute dosage of enrofloxacin.Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model.In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureusThe determinants of the antibiotic resistance process.Public health evolutionary biology of antimicrobial resistance: priorities for interventionIs selection relevant in the evolutionary emergence of drug resistance?The changing face of antibiotic prescribing: the mutant selection window.Effect of dosing and dosing frequency on the efficacy of ceftizoxime and the emergence of ceftizoxime resistance during the early development of murine abscesses caused by Bacteroides fragilis and Enterobacter cloacae mixed infectionIn vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.Recent developments in the clinical activity of topoisomerase-1 inhibitors.Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.Mutant selection window hypothesis updated.Drug interactions modulate the potential for evolution of resistance.Functional relationship between bacterial cell density and the efficacy of antibiotics.Tigecycline-Amikacin Combination Effectively Suppresses the Selection of Resistance in Clinical Isolates of KPC-Producing Klebsiella pneumoniae.A unified anti-mutant dosing strategy.Quinolones: action and resistance updated.Synergistic efficacy of Bisbenzimidazole and Carbonyl Cyanide 3-Chlorophenylhydrazone combination against MDR bacterial strains.Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada.Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.Pharmacokinetic and pharmacodynamic integration and modeling of acetylkitasamycin in swine for Clostridium perfringens.Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci.In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump.Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.Studying the effect of administration route and treatment dose on the selection of enrofloxacin resistance in commensal Escherichia coli in broilers.Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques.Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections.Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.
P2860
Q26771850-0CD900C9-31C1-4341-B554-B26E50ABFC08Q27319262-BAC83165-EB69-4F65-934C-0CE92C84B54BQ28552950-97AF8891-04B9-4414-811E-DDBD4E5783D3Q30911044-52EE71A5-FB5D-4662-B5D6-C54220D1FD1EQ33264145-F2B46AC1-CD5D-47D7-8C45-D89AC9AE66E8Q33792926-7FAABDD1-3D3C-4E4A-AD4C-D5E98F0AC3A8Q33836664-47F6E416-8750-4A8B-B038-3034E84CACE9Q34045286-867EBDA9-9A28-4933-AA6A-C7FF55DC1A6CQ34133191-AF824DCB-BE6A-44AD-BE69-710480BAC17AQ34596344-5808A302-A2B9-4E86-A7AE-D263896F8967Q34788573-BD959EF9-5F28-4F09-B171-E7E7451D1F3DQ34932274-41155B81-F606-482E-B830-E0566A1CAA77Q35026542-43A8D147-FE9C-4670-BADF-46CB230946DAQ35236703-B08BA3CA-A1F4-4286-A485-7B65CFB69EEEQ35826386-D10C3C74-CFB1-4BD6-B11B-FD31A43C33EDQ35875929-7FC2F9CC-711F-4090-98AB-66B5D4401B87Q36095024-8858ACF7-4660-4D24-B2BE-48C9F5169A98Q36187937-BB5A1275-F3E3-477B-899E-5B61BBF63AA4Q36234871-27974323-74DF-4BE5-B21E-4139C1CC7D0AQ36374300-A44CCD6E-EA61-4863-913D-1B238268ADF2Q36728061-869677E9-8244-4989-B493-E5F026FE35A3Q36937085-24C4FF8C-C253-4DFE-BAB7-495DE509FDE7Q37124158-9DD506F5-19A1-481F-B362-94DBC9DB07FBQ37188061-57C9B67B-9AA4-46C3-95C2-54E3D0F47C26Q37188136-A1CAFC89-714E-48A3-A493-88FD7DBEC0F7Q37595559-F9CF526F-C0EB-4BA7-B1F8-5845EB61A210Q37707919-5496DF67-9C96-41B3-9D2B-00771397AD47Q37713027-45EB1443-1A5B-458A-8E1E-9ACF49F7200FQ37733449-CF008371-421A-428D-8462-12B4C59248BEQ37988861-DD4C048B-5263-48BD-8844-BBA4EFBF792FQ38808661-D976C5BF-7B97-4E56-B28A-9114882EB8D0Q39396626-43C0F3F5-6362-45B0-BA32-F1B495A0F483Q39685988-CEED2C6B-7F73-4D10-8208-EB7D3FB583B7Q39730607-A1F60CDA-F727-408F-9F24-78214EF0A7BCQ39731893-E4D24B8B-DE0B-4003-A9A5-625C194D0A11Q40238353-0192551A-ACDA-4B7A-8657-36820AB3526AQ40289356-B4F9A324-6C83-48E9-863A-1AB847A1949AQ40410503-CC13DE2D-54C6-4F78-A19B-AD233A5442E5Q40499211-B07E0847-8CA4-4351-AB37-69FA1E64E7EBQ40631566-867F9FA0-4A80-4990-B641-DBB864AD3FE3
P2860
Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Restricting the selection of a ...... f the mutant selection window.
@en
Restricting the selection of a ...... f the mutant selection window.
@nl
type
label
Restricting the selection of a ...... f the mutant selection window.
@en
Restricting the selection of a ...... f the mutant selection window.
@nl
prefLabel
Restricting the selection of a ...... f the mutant selection window.
@en
Restricting the selection of a ...... f the mutant selection window.
@nl
P356
P1476
Restricting the selection of a ...... f the mutant selection window.
@en
P2093
Karl Drlica
P304
P356
10.1086/338571
P407
P50
P577
2002-01-31T00:00:00Z